Még nem toboroz
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
NCT07791732· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression
2025-524641-27-00· 3. fázis· K-Group Beta Inc.· Forrás
Toboroz
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
NCT07564141· 3. fázis· Genmab· Forrás
Toboroz
Proof-of-Concept Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of Intranasal Cenegermin in Adult Participants with moderate to severe Traumatic Brain Injury (TBI).
2025-522692-29-00· 2. fázis· Dompe' Farmaceutici S.p.A.· Forrás
Még nem toboroz
Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4
NCT07522697· 2. fázis· National Cancer Institute, Naples· Forrás
Toboroz
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )
2024-519818-31-01· 3. fázis· Genmab A/S· Forrás
Toboroz
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
NCT07225270· 3. fázis· Genmab· Forrás
Toboroz
Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01
NCT07290894· 2. fázis· National Cancer Institute, Naples· Forrás
Toboroz
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121· 2/3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
NCT07022483· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336· 3. fázis· AstraZeneca· Forrás
Toboroz
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755· 2/3. fázis· Exelixis· Forrás
Contact: Exelixis Clinical Trials
Toboroz
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568· 3. fázis· BioNTech SE· Forrás
Toboroz
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112· 3. fázis· AstraZeneca· Forrás
Toboroz
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236· 3. fázis· Genmab· Forrás
Fut, nem toboroz
MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer
NCT05233982· 2. fázis· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Forrás
Toboroz
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
NCT06545955· 3. fázis· Ferring Pharmaceuticals· Forrás
Toboroz
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
NCT06476808· 1. fázis· Bristol-Myers Squibb· Forrás
Fut, nem toboroz
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472· 1. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
NCT06072781· 3. fázis· Verastem, Inc.· Forrás
Toboroz
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025· 2/3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671· 3. fázis· AstraZeneca· Forrás
Még nem toboroz
Phase 2, open-label, multicentre, single-arm study to evaluate the activity of the combination of EGFR inhibitors and c-MET inhibitors in patients with platinum-resistant head and neck squamous cell carcinoma after relapse to immunotherapy.
2024-518892-72-00· 2. fázis· Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia· Forrás
Fut, nem toboroz
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778· 3. fázis· AbbVie· Forrás
Toboroz
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
NCT05548296· 2. fázis· Acrivon Therapeutics· Forrás
Fut, nem toboroz
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
NCT05201547· 3. fázis· ARCAGY/ GINECO GROUP· Forrás
Toboroz
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT05128825· 2. fázis· K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc· Forrás
Toboroz
MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.
NCT05255471· 3. fázis· National Cancer Institute, Naples· Forrás
Fut, nem toboroz
MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib, selected according to HRD status, in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination.
2024-516632-99-00· 2. fázis· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Forrás
Fut, nem toboroz
Randomized phase III trial on NIraparib-Dostarlimab vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO33)
2024-516649-38-00· 3. fázis· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Forrás
Toboroz
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
NCT03651206· 2/3. fázis· ARCAGY/ GINECO GROUP· Forrás
Contact: Isabelle RAY-COQUARD, Professor
Toboroz
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776· 1/2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797· 1/2. fázis· Eisai Inc.· Forrás
Fut, nem toboroz
accuRate Evaluation of Benefit With Optimal Medical Treatment With or Without Transcatheter Valve Repair of PARADOXical Low Flow Low Gradient Aortic Stenosis
NCT03863132· IHF GmbH - Institut für Herzinfarktforschung· Forrás
Toboroz
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT03564340· 1/2. fázis· Regeneron Pharmaceuticals· Forrás